Acalabrutinib - Acerta Pharma

Drug Profile

Acalabrutinib - Acerta Pharma

Alternative Names: ACP-196; CALQUENCE

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acerta Pharma
  • Developer Acerta Pharma; AstraZeneca; Biologics Inc; Merck Sharp & Dohme; University Hospital Southampton NHS Foundation Trust
  • Class Antineoplastics; Benzamides; Heavy metals; Imidazoles; Pyrazines; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Chronic lymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mantle-cell lymphoma
  • Phase III Chronic lymphocytic leukaemia
  • Phase II Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Rheumatoid arthritis; Waldenstrom's macroglobulinaemia
  • Phase I/II B cell lymphoma; B cell prolymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Glioblastoma; Multiple myeloma
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 05 Jun 2018 Acerta Pharma completes a phase II trial in Bladder cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (PO)
  • 01 Jun 2018 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in B-cell lymphoma presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 01 Jun 2018 Phase-I clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03527147)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top